DTAB Recommends To Form Sub-Committee To Examine Requirement Of RMP For Sales Of Cough Syrups

New Delhi : The Drugs Technical Advisory Board (DTAB) has recommended formation of a sub-committee to examine aspects including the requirement of Registered Medical Practitioner (RMP) for sale of various cough syrups in the country.

A recent meeting of the DTAB made the recommendation while looking into a representation received from Mumbai-based USV Pvt Ltd to move its approved drug Dried Ivy Leaf Extract Cough Syrup, from prescription drug to the Schedule K of the Drugs and Cosmetics Rules, 1945.

USV has requested for marketing of approved drug “Dried Ivy Leaf Extract Cough Syrup” under Schedule K (Rule 123) and requested exemption from the “WARNING: “To be sold by retail on the prescription of a RMP only”

It has also submitted the proposal and a recommendation from the Subject Expert Committee for the consideration of the Board.

“DTAB deliberated the matter and recommended that a sub-committee should be constituted to examine the proposal and also to examine the requirement of RMP for sale of various cough syrups in the country,” concluded the Board.

The SEC, which advises the drug regulator on matters related to Pulmonary therapeutic segment, in its 60th meeting on June 7, 2022, recommended for exemption of the drug from ‘Warning’ label requirement for marketing of the cough syrup. It also opined that an opinion from a phytopharmaceutical expert may be obtained for further proceedings.

Prior to the recommendation, the company presented patient safety data, details of concentration of Saponin in the reduction and the details of countries in which the product is marketed, package insert and regulatory status before the committee.

USV sells Prospan brand of dried ivy leaf extract based cough syrup in the market. The company, in its website claims that the exclusive extract from the leaves is carefully made using a patented extraction process and backed by years of clinical research.

It may be noted that the decision to look into the requirement of RMP for the same of various cough syrups in the country comes at a time when there has been an increased focus on the quality of cough syrups manufactured and exported from the country.

Related Posts

Indian Pharma Majors Plan to Invest in US

National Harbor (US): Top Indian pharmaceutical companies, including at least three from Hyderabad, are all set to announce major investments to set up new facilities in the United States during…

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Emcure Pharmaceuticals Ltd on Tuesday reported a 24 per cent increase in consolidated net profit at ₹243.74 crore in the fourth quarter ended March 2026 on the back of robust…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Indian Pharma Majors Plan to Invest in US

Indian Pharma Majors Plan to Invest in US

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Emcure Pharmaceuticals Q4 net profit rises 24% to ₹243.74 cr

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

Fake Cancer Drug Racket: Delhi HC Grants Bail, Flags Gaps in ED Probe

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification